Epidemiology of Ciprofloxacin Resistance and its Relationship to Extended-Spectrum β-Lactamase Production in Proteus mirabilis Bacteremia

Korean Journal of Internal Medicine

Volumn 26, Issue 1, 2011, Pages 89-93

  Sohn, Kyung Mok ^a,b   Kang, Cheol In ^a   Joo, Eun Jeong ^a   Ha, Young Eun ^a   Chung, Doo Ryeon ^a   Peck, Kyong Ran ^a   Lee, Nam Yong ^a   Song, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

Author keywords

Bacterial; Cephalosporin resistance; Ciprofloxacin; Drug resistance; Proteus mirabilis; Risk factors

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CORTICOSTEROID; EXTENDED SPECTRUM BETA LACTAMASE;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COMMUNICABLE DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MISUSE; ENZYME SYNTHESIS; FEMALE; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; INDWELLING CATHETER; INFECTION RISK; INFECTION SENSITIVITY; MALE; NEUROLOGIC DISEASE; NONHUMAN; PATIENT IDENTIFICATION; PNEUMONIA; POSTOPERATIVE PERIOD; PROTEUS INFECTION; PROTEUS MIRABILIS; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-INFECTIVE AGENTS; BACTEREMIA; BETA-LACTAMASES; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEUS INFECTIONS; PROTEUS MIRABILIS; RISK FACTORS;

EID: 79953276490     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.1.89     Document Type: Article

References (23)

1. Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005;49:2598-2605.
2. O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 2000;13:534-546.
3. Wu JJ, Chen HM, Ko WC, Wu HM, Tsai SH, Yan JJ. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66). Diagn Microbiol Infect Dis 2008;60:169-175.
4. Uh Y, Hwang GY, Kwon O, Yoon KJ, Kim HY. Isolation frequency of extended spectrum beta-lactamase producing Escherichia coli, Klebsiella species, and Proteus mirabilis. Korean J Clin Microbiol 2007;10:119-122.
5. Hernandez JR, Martinez-Martinez L, Pascual A, Suarez AI, Perea EJ. Trends in the susceptibilities of Proteus mirabilis isolates to quinolones. J Antimicrob Chemother 2000;45:407-408.
6. Saito R, Okugawa S, Kumita W, et al. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients. Clin Microbiol Infect 2007;13:1204-1206.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement (Document M100-S17). Wayne (PA): Clinical and Laboratory Standards Institute, 2007.
8. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-797.
9. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-478.
10. Kang CI, Kim SH, Kim DM, et al. Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2004;10:71-76.
11. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288-1294.
12. Kang CI, Kim SH, Park WB, et al. Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species. Infect Control Hosp Epidemiol 2005;26:88-92.
13. Kim JY, Park YJ, Kim SI, Kang MW, Lee SO, Lee KY. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital. J Antimicrob Chemother 2004;54:1144-1147.
14. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009;30:746-752.
15. Tacconelli E, De Angelis G, Cataldo MA, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009;53:4264-4269.
16. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93.
17. Jacoby G, Cattoir V, Hooper D, et al. qnr Gene nomenclature. Antimicrob Agents Chemother 2008;52:2297-2299.
18. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797-799.
19. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother 2009;53:639-645.
20. Wu JJ, Ko WC, Wu HM, Yan JJ. Prevalence of Qnr determinants among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae in a Taiwanese hospital, 1999-2005. J Antimicrob Chemother 2008;61:1234-1239.
21. Wang M, Guo Q, Xu X, et al. New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 2009;53:1892-1897.
22. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community- acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008;36:41-45.
23. Levin PD, Fowler RA, Guest C, Sibbald WJ, Kiss A, Simor AE. Risk factors associated with resistance to ciprofloxacin in clinical bacterial isolates from intensive care unit patients. Infect Control Hosp Epidemiol 2007;28:331-336.